info@3helix.com
Pancreatic Ductal Adenocarcinoma (PDAC) remains a formidable challenge in oncology; characterized by its aggressive nature, early metastasis, and resistance to conventional therapeutic modalities. Despite being one of the most fatal cancers, PDAC research and treatment development have been hampered by the inability to make early diagnoses, improved clinical prognoses, and create effective treatment plans.
Collagen Hybridizing Peptides (CHPs) selectively target and quantify degraded collagen, a critical component of PDAC tumors, to improve our understanding of PDAC tumor dynamics. Researchers can use CHPs to conduct studies not only into the progression of PDAC tumors over time, but can also use CHPs to quantify a reduction in fibrosis as a response to treatment, making them powerful tools to improve patient survivability.
Subrahmanyam, Nithya Bala. Water Soluble Polymer-Collagen Hybridizing Peptide Conjugates for Targeting the Tumor Extracellular Matrix. Diss. The University of Utah, 2023.
Ouellette, Jonathan N., et al. "Navigating the collagen jungle: the biomedical potential of fiber organization in cancer." Bioengineering 8.2 (2021): 17.
Isaacson, Kyle J., et al. "Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression." Journal of Controlled Release 259 (2017): 62-75.
Thanks for subscribing!
This email has been registered!